Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $33.1667.

A number of analysts have recently issued reports on the company. Raymond James Financial began coverage on Tyra Biosciences in a report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $35.00 target price for the company. Wedbush raised their price target on shares of Tyra Biosciences from $30.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Wall Street Zen raised shares of Tyra Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Oppenheimer reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Tyra Biosciences in a research note on Wednesday, September 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, October 8th.

Tyra Biosciences Stock Down 0.5%

Shares of NASDAQ TYRA opened at $25.38 on Tuesday. The stock’s fifty day simple moving average is $18.39 and its 200 day simple moving average is $13.82. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -13.57 and a beta of 1.08. Tyra Biosciences has a 52-week low of $6.42 and a 52-week high of $26.09.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, meeting analysts’ consensus estimates of ($0.50). As a group, analysts anticipate that Tyra Biosciences will post -1.57 earnings per share for the current year.

Insider Buying and Selling at Tyra Biosciences

In related news, Director Robert J. More sold 246,871 shares of Tyra Biosciences stock in a transaction on Friday, November 21st. The shares were sold at an average price of $20.25, for a total value of $4,999,137.75. Following the completion of the sale, the director owned 3,833,425 shares of the company’s stock, valued at approximately $77,626,856.25. The trade was a 6.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 15.20% of the company’s stock.

Institutional Trading of Tyra Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in TYRA. Commodore Capital LP increased its holdings in shares of Tyra Biosciences by 8.9% during the 3rd quarter. Commodore Capital LP now owns 3,375,000 shares of the company’s stock valued at $47,216,000 after acquiring an additional 275,000 shares during the last quarter. Vestal Point Capital LP boosted its position in shares of Tyra Biosciences by 190.9% during the 1st quarter. Vestal Point Capital LP now owns 2,879,829 shares of the company’s stock valued at $26,782,000 after acquiring an additional 1,889,829 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Tyra Biosciences by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company’s stock worth $21,267,000 after purchasing an additional 118,492 shares in the last quarter. Balyasny Asset Management L.P. raised its position in Tyra Biosciences by 45.1% in the 3rd quarter. Balyasny Asset Management L.P. now owns 846,585 shares of the company’s stock valued at $11,844,000 after purchasing an additional 263,199 shares during the last quarter. Finally, Sio Capital Management LLC grew its stake in shares of Tyra Biosciences by 94.5% during the second quarter. Sio Capital Management LLC now owns 810,274 shares of the company’s stock valued at $7,754,000 after purchasing an additional 393,657 shares during the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.